Occurrence of acute myeloid leukemia in hydroxyurea-treated sickle cell disease patient

Samuel Regan, Xuebin Yang, Niklas K. Finnberg, Wafik S. El-Deiry, Jeffrey J. Pu

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Hydroxyurea (HU) has been widely used in sickle cell disease. Its potential long-term risk for carcinogenesis or leukemogenic risk remains undefined. Here, we report a 26 y old African-American female with Sickle Cell Disease (SCD) who developed refractory/relapsed acute myeloid leukemia (AML) 6 months after 26 months of HU use. That patient’s cytogenetics and molecular genetics analyses demonstrated a complex mutation profile with 5q deletion, trisomy 8, and P53 deletion (deletion of 17p13.1). P53 gene sequence studies revealed a multitude of somatic mutations that most suggest a treatment-related etiology. The above-mentioned data indicates that the patient may have developed acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) as a direct result of HU exposure.

Original languageEnglish (US)
Pages (from-to)1389-1397
Number of pages9
JournalCancer Biology and Therapy
Volume20
Issue number11
DOIs
StatePublished - Nov 2 2019
Externally publishedYes

Keywords

  • acute myeloid leukemia with myelodysplasia-related changes
  • Hydroxyurea
  • P53 gene
  • sickle cell disease

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Occurrence of acute myeloid leukemia in hydroxyurea-treated sickle cell disease patient'. Together they form a unique fingerprint.

Cite this